GlassScriptPhysician profile
Evan S Corey
NPI 1801116884
$1,836.85
in general payments reported to CMS, 2019-2025
27 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
See the full distribution for Sports Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $565 · 2021: $38.85 · 2022: $37.90 · 2023: $35.44 · 2024: $199 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $414.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $414.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $455.04 | 2019-2025 | Evenity, Prolia, Prolia |
| Novo Nordisk INC | $177.48 | 2019-2020 | |
| Pfizer INC. | $140.04 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $126.73 | 2019-2020 | |
| Radius Health, INC. | $91.13 | 2024-2025 | Tymlos |
| Depuy Synthes Sales INC. | $90.44 | 2019-2025 | Monovisc, Orthovisc |
| Glaxosmithkline, LLC. | $86.17 | 2019-2020 | |
| Lilly USA, LLC | $77.84 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $64.71 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $56.63 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $54.73 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $54.02 | 2019-2020 | |
| Eisai INC. | $52.76 | 2019-2020 | |
| Almatica Pharma LLC | $38.90 | 2025 | Teriparatide |
| Astellas Pharma US INC | $36.86 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $33.37 | 2020 | |
| Ermi LLC | $23.25 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.62 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $22.60 | 2023 | Iovera, Zilretta |
| Regeneron Healthcare Solutions, INC. | $22.48 | 2019 | |
| Abbvie INC. | $21.80 | 2025 | |
| Boston Scientific Corporation | $19.70 | 2025 | General - Pain Management |
| Tenex Health INC. | $15.72 | 2019 | |
| Amarin Pharma, INC. | $15.55 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.59 | 2020 | |
| Genentech USA, INC. | $12.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $11.23 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Evan Corey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.